Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
暂无分享,去创建一个
Bin Tean Teh | Choon Kiat Ong | C. Ong | B. Teh | S. Rozen | P. Tan | W. K. Lim | Patrick Tan | Steven G Rozen | Apinya Jusakul | Sarinya Kongpetch | Weng Khong Lim | A. Jusakul | S. Kongpetch
[1] Tong Wu,et al. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. , 2015, The Journal of Biological Chemistry.
[2] Kosei Maemura,et al. Molecular mechanism of cholangiocarcinoma carcinogenesis , 2014, Journal of hepato-biliary-pancreatic sciences.
[3] J. Fitzgibbon,et al. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies , 2014, Expert opinion on investigational drugs.
[4] K. Ross,et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.
[5] Hao Yin,et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.
[6] Y. Totoki,et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.
[7] Jin‐Young Jang,et al. 22q11-q13 as a hot spot for prediction of disease-free survival in bile duct cancer: integrative analysis of copy number variations. , 2014, Cancer genetics.
[8] G. Riggins,et al. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells , 2014, Tumor Biology.
[9] Eric W. Klee,et al. Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.
[10] Christopher R. Schmidt,et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway , 2014, Hepatology.
[11] G. Gores,et al. Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.
[12] Timothy M Pawlik,et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. , 2013, Human pathology.
[13] Swe Swe Myint,et al. Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.
[14] T. Pawlik,et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.
[15] S. Lowe,et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target , 2013, Proceedings of the National Academy of Sciences.
[16] Jeffrey A. Engelman,et al. Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.
[17] S. Thorgeirsson,et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. , 2013, Gastroenterology.
[18] Jesse S. Voss,et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. , 2013, Human pathology.
[19] Geraint T. Williams,et al. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies , 2013, The Journal of pathology.
[20] Nickolay A. Khazanov,et al. Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.
[21] Maylee Hsu,et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas , 2013, Cancer.
[22] Rameen Beroukhim,et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.
[23] Sayaka Sekiya,et al. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. , 2012, The Journal of clinical investigation.
[24] Lincoln D. Stein,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.
[25] Erik Schrumpf,et al. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma , 2012, Epigenetics.
[26] H. Clevers,et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors , 2012, Nature.
[27] G. Gores,et al. Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.
[28] B. Li,et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis , 2012, BMC Cancer.
[29] Tong Wu,et al. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. , 2012, Gastroenterology.
[30] Derek Y. Chiang,et al. Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.
[31] Bin Tean Teh,et al. Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.
[32] S. Thorgeirsson,et al. Genetic profiling of intrahepatic cholangiocarcinoma , 2012, Current opinion in gastroenterology.
[33] A. Zhu,et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. , 2012, Cancer research.
[34] Justin L. Mott,et al. miR‐25 targets TNF‐related apoptosis inducing ligand (TRAIL) death receptor‐4 and promotes apoptosis resistance in cholangiocarcinoma , 2012, Hepatology.
[35] Hui Li,et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. , 2012, Gene.
[36] Liu Xiaofang,et al. Correlation between promoter methylation of p14ARF, TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma , 2012, World Journal of Surgical Oncology.
[37] M. Takamura,et al. Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM. , 2011, Cancer letters.
[38] K. Unger,et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[39] D. Calvisi,et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.
[40] M. Asaka,et al. RNF43 interacts with NEDL1 and regulates p53-mediated transcription. , 2011, Biochemical and biophysical research communications.
[41] Jian Yu,et al. Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma , 2011, PloS one.
[42] Jing Xu,et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. , 2010, World journal of hepatology.
[43] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[44] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[45] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[46] M. Wilm,et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB , 2010, Nature.
[47] Mark D. Johnson,et al. The Imprinted Gene PEG3 Inhibits Wnt Signaling and Regulates Glioma Growth* , 2010, The Journal of Biological Chemistry.
[48] Ximing J. Yang,et al. p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion , 2009, International journal of cancer.
[49] Y. Mizuguchi,et al. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. , 2009, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[50] B. Sander,et al. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. , 2009, Human pathology.
[51] G. Gores,et al. MicroRNA‐21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3 , 2009, Hepatology.
[52] L. Roberts,et al. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[53] M. Matsuda,et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.
[54] Banchob Sripa,et al. Liver Fluke Induces Cholangiocarcinoma , 2007, PLoS medicine.
[55] T. Tsukamoto,et al. Chromosomal instability by β-catenin/TCF transcription in APC or β-catenin mutant cells , 2007, Oncogene.
[56] T. Patel,et al. The MicroRNA let-7a Modulates Interleukin-6-dependent STAT-3 Survival Signaling in Malignant Human Cholangiocytes* , 2007, Journal of Biological Chemistry.
[57] T. Limpaiboon,et al. Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. , 2006, World journal of gastroenterology.
[58] M. Miwa,et al. Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. , 2006, World journal of gastroenterology.
[59] T. Limpaiboon,et al. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. , 2006, World journal of gastroenterology.
[60] G. Gores,et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. , 2006, The Journal of clinical investigation.
[61] R. DePinho,et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. , 2006, Cancer research.
[62] Tushar Patel,et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.
[63] S. Holt,et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. , 2005, Gastroenterology.
[64] Pawel Stankiewicz,et al. Genomic Disorders: Molecular Mechanisms for Rearrangements and Conveyed Phenotypes , 2005, PLoS genetics.
[65] K. McGlynn,et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. , 2005, Gastroenterology.
[66] J. Herman,et al. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma , 2005, Modern Pathology.
[67] Chien-Hua Chen,et al. Relation of hepatolithiasis to helminthic infestation , 2005, Journal of gastroenterology and hepatology.
[68] K. Mizumoto,et al. Immunohistochemical Study of DPC4 and p53 Proteins in Gallbladder and Bile Duct Cancers , 2004, World Journal of Surgery.
[69] R. Semba,et al. Mechanism of NO-mediated oxidative and nitrative DNA damage in hamsters infected with Opisthorchis viverrini: a model of inflammation-mediated carcinogenesis. , 2004, Nitric oxide : biology and chemistry.
[70] R. Semba,et al. Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2'-deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. , 2004, Carcinogenesis.
[71] H. El‐Serag,et al. The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.
[72] Keara M. Lane,et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) , 2003, Genes, chromosomes & cancer.
[73] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[74] M. Cleary,et al. Novel SWI/SNF Chromatin-Remodeling Complexes Contain a Mixed-Lineage Leukemia Chromosomal Translocation Partner , 2003, Molecular and Cellular Biology.
[75] A. Rashid,et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] Hwoong-Yong Jung,et al. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. , 2002, The American journal of pathology.
[77] F. Sommerer,et al. Genetic and epigenetic alterations of the INK4a–ARF pathway in cholangiocarcinoma , 2002, The Journal of pathology.
[78] M. Tsuneyoshi,et al. c‐erbB‐2 and c‐Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma , 2002, Histopathology.
[79] P. Vatanasapt,et al. Cancer control in Thailand. , 2002, Japanese journal of clinical oncology.
[80] Y. Rao,et al. Signal Transduction in Neuronal Migration Roles of GTPase Activating Proteins and the Small GTPase Cdc42 in the Slit-Robo Pathway , 2001, Cell.
[81] C. Ihm,et al. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2001, Cancer genetics and cytogenetics.
[82] A. Tannapfel,et al. Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver , 2000, Gut.
[83] X. Wu,et al. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[84] K. Chayama,et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis , 2000, Cancer.
[85] R. Reddel,et al. p16(INK4a) and the control of cellular proliferative life span. , 1999, Carcinogenesis.
[86] J. Massagué,et al. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.
[87] G. Crabtree,et al. Diversity and specialization of mammalian SWI/SNF complexes. , 1996, Genes & development.
[88] S. Tannenbaum,et al. DNA damage by nitric oxide. , 1996, Chemical research in toxicology.
[89] S. Hanai,et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. , 1995, Cancer research.
[90] Michael R. Green,et al. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex , 1994, Nature.
[91] B. Sripa,et al. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[92] Jeffrey W. Clark,et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.
[93] F. Vleggaar,et al. High lifetime risk of cancer in primary sclerosing cholangitis. , 2009, Journal of hepatology.
[94] G. Gores,et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. , 2007, Gastroenterology.
[95] D. Wink,et al. Direct and indirect effects of nitric oxide in chemical reactions relevant to biology. , 1996, Methods in enzymology.
[96] S. Hirohashi,et al. Cholangiocarcinomas in japanese and thai patients: Difference in etiology and incidence of point mutation of the c‐KI‐ras proto‐oncogene , 1992, Molecular carcinogenesis.